Adjuvant IO: The "Big News" of Survival Advantage in Renal Cancer.

Published Date: 16 Mar 2024

The greatest finding from ASCO GU 2024, according to Dr. Brian Rini, is a forty percent lower risk of dying from renal cancer (KEYNOTE-564). Developments in doublet therapy for advanced disease are also covered.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot